Phio Pharmaceuticals
PHIO
15 hedge funds and large institutions have $1.82M invested in Phio Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 5 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
25% more call options, than puts
Call options by funds: $447K | Put options by funds: $359K
15% more capital invested
Capital invested by funds: $1.58M → $1.82M (+$240K)
0.01% more ownership
Funds ownership: 0.05% → 0.06% (+0.01%)
12% less funds holding
Funds holding: 17 → 15 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$218K |
| 2 |
Two Sigma Advisers
New York
|
+$185K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$58.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$38.2K |
| 5 |
VF
Virtu Financial
New York
|
+$35.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$54K |
| 2 |
Goldman Sachs
New York
|
-$43K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$39K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$21.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$19.2K |
PHIO Hedge Fund Activity: Q3 2021 in Review
15 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2021, worth a combined $1.82M — up 15% from $1.58M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PHIO and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Millennium Management, adding an estimated $218K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $54K sold.
- 15 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2021, down from 17 in Q2 2021.
- Funds reported $1.82M of Phio Pharmaceuticals stock for Q3 2021, up 15% quarter-over-quarter.
- 3 funds opened new Phio Pharmaceuticals positions in Q3 2021 and 5 closed out, a net change of -2 holders.
- The largest Phio Pharmaceuticals buyer in Q3 2021 was Millennium Management, an estimated $218K added.
- The largest Phio Pharmaceuticals seller in Q3 2021 was Dimensional Fund Advisors, an estimated $54K sold.
Based on aggregated 13F filings for Q3 2021.